Webinar on Infex's Phase II lead respiratory drug, RESP-X

On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…


Infex Therapeutics logo

Infex to present webinar on lead Phase II respiratory drug RESP-X

RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the…


RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Clinical candidate nominated for COV-X programme

COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…


Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

Listen to the podcast here Infex CEO Peter Jackson discusses the state of…


Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Antimicrobial discovery and drug development - RSC Podcast

How do we develop drugs like antibiotics? How long does it take for such a drug…


Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…